Macrophages/Monocytes antibody | MOMA-2

100% Secure


Rat anti Mouse Macrophages/Monocytes:Alexa Fluor® 488

Rat anti Mouse Macrophages/Monocytes:Alexa Fluor® 647

Rat anti Mouse Macrophages/Monocytes:FITC

Rat anti Mouse Macrophages/Monocytes

Rat anti Mouse Macrophages/Monocytes:RPE

Rat anti Mouse Macrophages/Monocytes:Alexa Fluor® 700

Product Type
Monoclonal Antibody
Clone
MOMA-2
Isotype
IgG2b
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
MCA519A488T F* 25 Tests/0.25ml
MCA519A488 F* 100 Tests/1ml
MCA519A647T F* 25 Tests/0.25ml
MCA519A647 F* 100 Tests/1ml
MCA519FA F* 50 µg
MCA519F F 0.1 mg
MCA519GT C F* IF 25 µg
MCA519G C F* IF 0.25 mg
MCA519PET F* 25 Tests
MCA519PE F* 100 Tests
MCA519A700T F* 25 Tests/0.25ml
MCA519A700 F* 100 Tests/1ml
Rat anti Mouse Macrophages/Monocytes antibody, clone MOMA-2 recognizes an intracellular antigen of mouse macrophages and monocytes. It reacts strongly with macrophages in lymphoid organs such as tingible body macrophages and macrophages in T cell dependant areas and is extremely useful in immunohistochemistry. Reacts on all mouse strains tested.

Product Details

Target Species
Mouse
Product Form
Purified IgG conjugated to Alexa Fluor®488 - liquid
Product Form
Purified IgG conjugated to Alexa Fluor® 647 - liquid
Product Form
Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
Product Form
Purified IgG - liquid
Product Form
Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
Product Form
Purified IgG conjugated to Alexa Fluor® 700 - liquid
Reconstitution
Pack Size: 25 Tests
Reconstitute with 0.25 ml distilled water
Pack Size: 100 Tests
Reconstitute with 1 ml distilled water
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Immunogen
Mouse lymph node stroma.
Approx. Protein Concentrations
IgG concentration 0.05mg/ml
Approx. Protein Concentrations
IgG concentration 0.05mg/ml
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
IgG concentration 0.5 mg/ml
Approx. Protein Concentrations
IgG concentration 0.05mg/ml
Fusion Partners
Spleen cells from immunised Wistar rats were fused with cells of the SP/0 myeloma cell line.

Storage Information

Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Prior to reconstitution store at +4oC.
Following reconstitution store at +4oC.
DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
12 months from date of reconstitution.
Shelf Life
18 months from date of despatch.

More Information

Acknowledgements
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
Acknowledgements
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
Acknowledgements
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
Regulatory
For research purposes only

Applications of Macrophages/Monocytes antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry 1 Neat 1/10
Flow Cytometry 1 Neat 1/10
Flow Cytometry 1 Neat 1/10
Flow Cytometry 1
Immunofluorescence
Immunohistology - Frozen 1/25
Flow Cytometry 1 Neat 1/10
Flow Cytometry 1 Neat 1/10
  1. 1Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
  1. 1Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
  1. 1Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
  1. 1Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
  1. 1Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
  1. 1Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

*Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm (Product Code BUF09) for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

*Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm (Product Code BUF09) for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

*Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm (Product Code BUF09) for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

*Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm (Product Code BUF09) for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

*Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm (Product Code BUF09) for this purpose.
Flow Cytometry
Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.

Secondary Antibodies Available

Description Product Code Pack Size Applications List Price Quantity
Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed) STAR131A 1 ml C E P WB
Goat anti Rat IgG:Biotin (Mouse Adsorbed) STAR131B 0.5 mg C E IF P WB
Rabbit F(ab')2 anti Rat IgG:Dylight®800 STAR16D800GA 0.1 mg F IF WB
Rabbit F(ab')2 anti Rat IgG:FITC STAR17B 1 mg F
Rabbit F(ab')2 anti Rat IgG:HRP STAR21B 1 mg C E P RE
Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed) STAR69 0.5 ml F
Goat anti Rat IgG:DyLight®649 (Mouse Adsorbed) STAR71D649GA 0.1 mg F IF
Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed) STAR71D800GA 0.1 mg F IF WB
Goat anti Rat IgG:HRP (Mouse Adsorbed) STAR72 0.5 mg C E P
Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed) STAR73 0.5 ml F

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Mouse Seroblock FcR BUF041A 0.1 mg F
Mouse Seroblock FcR BUF041B 0.5 mg F
Mouse Seroblock FcR BUF041A 0.1 mg F
Mouse Seroblock FcR BUF041B 0.5 mg F
Mouse Seroblock FcR BUF041A 0.1 mg F
Mouse Seroblock FcR BUF041B 0.5 mg F
Mouse Seroblock FcR BUF041A 0.1 mg F
Mouse Seroblock FcR BUF041B 0.5 mg F
Mouse Seroblock FcR BUF041A 0.1 mg F
Mouse Seroblock FcR BUF041B 0.5 mg F

Application Based External Images

Flow Cytometry

Immunofluorescence

Immunohistology - Frozen

Immunohistology - Paraffin

Product Specific References

Source Reference

  1. Kraal, .G .et al. (1987) Macrophages in T and B cell compartments and other tissue macrophages recognized by monoclonal antibody MOMA-2. An immunohistochemical study.
    Scand J Immunol. 26 (6): 653-61.

References for Macrophages/Monocytes antibody

  1. van der Sluis, R.J. et al. (2014) Prolactin receptor antagonism uncouples lipids from atherosclerosis susceptibility.
    J Endocrinol. 222 (3): 341-50.
  2. Nakai, Y. et al. (2004) Natural killer T cells accelerate atherogenesis in mice.
    Blood. 104 (7): 2051-9.
  3. Skoura, A. et al. (2011) Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis.
    Arterioscler Thromb Vasc Biol. 31 (1): 81-5.
  4. Madrigal-Matute, J. et al. (2010) Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
    Cardiovasc Res. 86 (2): 330-7.
  5. de Jager, S.C. et al. (2011) Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis.
    J Exp Med. 208 (2): 217-25.
  6. Frossard, J.L. et al. (2011) Role of CCL-2, CCR-2 and CCR-4 in cerulein-induced acute pancreatitis and pancreatitis-associated lung injury.
    J Clin Pathol. 64 (5): 387-93.
  7. Bhatia, V.K. et al (2007) Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Am J Pathol.170: 416-26.
  8. Bourdillon, M.C. et al. (2006) Reduced atherosclerotic lesion size in P-selectin deficient apolipoprotein E-knockout mice fed a chow but not a fat diet.
    J Biomed Biotechnol. 2006 (2): 49193.
  9. Duewell, P. et al. (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
    Nature. 464: 1357-61.
  10. Weingärtner, O. et al. (2011) Differential effects on inhibition of cholesterol absorption by plant stanol and plant sterol esters in apoE-/- mice.
    Cardiovasc Res. 90: 484-92.
  11. Yamamoto, S. et al. (2011) Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice.
    Nephrol Dial Transplant. 26 (8): 2491-7.
  12. Ng, H.P. et al. (2011) Attenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells.
    J Immunol. 187 (11): 6082-93.
  13. Ruf, M.T. et al. (2012) Chemotherapy-Associated Changes of Histopathological Features of Mycobacterium ulcerans Lesions in a Buruli Ulcer Mouse Model.
    Antimicrob Agents Chemother. 56: 687-96.
  14. Che, J. et al. (2011) Endothelial FGF receptor signaling accelerates atherosclerosis.
    Am J Physiol Heart Circ Physiol. 300: H154-61.
  15. Chen, S. (2010) IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice.
    J Immunol. 185: 5619-27.
  16. Dieleman, L.A. et al. (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines.
    Clin Exp Immunol. 114: 385-91.
  17. Gao, Q. et al. (2010) A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice.
    J Immunol. 185: 5820-7.
  18. Pedersen, T.X. et al. (2010) The pro-inflammatory effect of uraemia overrules the anti-atherogenic potential of immunization with oxidized LDL in apoE-/- mice.
    Nephrol Dial Transplant. 25: 2486-91.
  19. Lee, M.R. et al. (2014) The adipokine Retnla modulates cholesterol homeostasis in hyperlipidemic mice.
    Nat Commun. 5: 4410.
  20. Hoeksema, M.A. et al. (2014) Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions.
    EMBO Mol Med. 6 (9): 1124-32.
  21. Yamamoto, S. et al. (2015) Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype
    Atherosclerosis. 242 (1): 56-64.
  22. Babaei, S. et al. (2000) Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation.
    Cardiovasc Res. 2000 Oct;48: 158-67.
  23. Wan W et al. (2015) Atypical chemokine receptor 1 deficiency reduces atherogenesis in ApoE-knockout mice.
    Cardiovasc Res. 106 (3): 478-87.
  24. Krishack, P.A. et al. (2015) Serum Amyloid A Facilitates Early Lesion Development in Ldlr-/- Mice.
    J Am Heart Assoc. 4 (7): pii: e001858.
  25. Aoki, S. et al. (2015) Oral administration of the β-glucan produced by Aureobasidium pullulans ameliorates development of atherosclerosis in apolipoprotein E deficient mice
    Journal Funct Foods. 18: 22-7.
  26. Song, G. et al. (2015) Molecular hydrogen stabilizes atherosclerotic plaque in low-density lipoprotein receptor-knockout mice.
    Free Radic Biol Med. 87: 58-68.
  27. Takata, H. et al. (2015) Vascular angiotensin II type 2 receptor attenuates atherosclerosis via a kinin/NO-dependent mechanism.
    J Renin Angiotensin Aldosterone Syst. 16 (2): 311-20.
  28. Wezel, A. et al. (2015) Mast cells mediate neutrophil recruitment during atherosclerotic plaque progression.
    Atherosclerosis. 241 (2): 289-96.
  29. Oguiza A et al. (2015) Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.
    Diabetologia. 58 (7): 1656-67.
  30. Shuto, Y. et al. (2015) Repetitive Glucose Spikes Accelerate Atherosclerotic Lesion Formation in C57BL/6 Mice.
    PLoS One. 10 (8): e0136840.
  31. Peng, Y. et al. (2016) Inactivation of Semicarbazide-Sensitive Amine Oxidase Stabilizes the Established Atherosclerotic Lesions via Inducing the Phenotypic Switch of Smooth Muscle Cells.
    PLoS One. 11 (4): e0152758.
  32. Hong, Y.F. et al. (2016) Lactobacillus acidophilus K301 Inhibits Atherogenesis via Induction of 24 (S), 25-Epoxycholesterol-Mediated ABCA1 and ABCG1 Production and Cholesterol Efflux in Macrophages.
    PLoS One. 11 (4): e0154302.
  33. Grootaert, M.O. et al. (2016) NecroX-7 reduces necrotic core formation in atherosclerotic plaques of Apoe knockout mice.
    Atherosclerosis. 252: 166-74.
  34. Oguro, A. et al. (2003) NaF induces early differentiation of murine bone marrow cells along the granulocytic pathway but not the monocytic or preosteoclastic pathway in vitro.
    In Vitro Cell Dev Biol Anim. 39 (5-6): 243-8.
  35. van der Sluis, R.J. et al. (2015) Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice.
    Br J Pharmacol. 172 (9): 2397-405.
  36. Addison, C.L. et al. (2004) Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis.
    BMC Cancer. 4: 28.